Sanofi to focus on 12 blockbuster drug candidates, immunology pipeline – ET HealthWorld | Pharma
New Delhi: Sanofi said on Thursday it will focus on 12 potential blockbuster drug candidates and prioritise development in immunology,…
dupixent
Continue reading
Sanofi looks to widen Dupixent use to treat ‘smoker’s lung’ after second trial win – ET HealthWorld | Pharma
New Delhi: Sanofi plans to seek U.S. approval for it best-selling anti-inflammatory drug Dupixent to be used in the treatment…
More public awareness is required for innovative treatments for difficult-to-treat illnesses like atopic dermatitis: Anil Raina, Sanofi – ET HealthWorld
Shahid Akhter, editor, ETHealthworld, spoke to Anil Raina, General Manager (Speciality Care), Sanofi, to know more about the advancements in…
Sanofi receives marketing approval for Dupixent in India – ET HealthWorld | Pharma
Mumbai: Sanofi Healthcare India Pvt. Ltd. on Tuesday announced that they have obtained marketing approval for Dupixent (dupilumab). This marks…
Sanofi says global head of R&D to leave company – ET HealthWorld
Paris: Sanofi on Monday said its global head of research and development, John Reed, has decided to step down, after…
Sanofi sees faster profit growth on Dupixent, flu vaccine – ET HealthWorld
Paris: French drugmaker Sanofi on Friday forecast faster earnings growth this year on strong demand for its bestselling drug Dupixent…